Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Therapeutics Secures $20M for Stenoparib's FDA Approval
    Allarity Therapeutics Secures $20M for Stenoparib's FDA Approval

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3250989/0/en/Allarity-Therapeutics-Closes-20-Million-Financing-to-Accelerate-the-Advance-of-Stenoparib-Toward-FDA-Approval-and-Commercialization.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230960/0/en/Allarity-Therapeutics-announces-that-its-collaborative-Phase-2-trial-with-the-United-States-Veteran-s-Administration-Combining-Stenoparib-with-Temozolomide-in-Relapsed-Small-Cell-L.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Allarity Therapeutics Unveils Q3 Financials & Business Update
    Allarity Therapeutics Unveils Q3 Financials & Business Update

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188337/0/en/Allarity-Therapeutics-Provides-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    Allarity Therapeutics Unveils Stenoparib/2x-121 Phase 2 Data:
    Allarity Therapeutics Unveils Stenoparib/2x-121 Phase 2 Data:

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153846/0/en/Allarity-Therapeutics-Presents-New-Phase-2-Clinical-Data-for-Stenoparib-2X-121-Showing-Landmark-Median-Overall-Survival-Has-Now-Surpassed-25-Months.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Allarity CEO to Present at Biomarkers & Precision Medicine 2025
    Allarity CEO to Present at Biomarkers & Precision Medicine 2025

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151554/0/en/Allarity-Therapeutics-CEO-to-Present-at-Biomarkers-Precision-Medicine-2025.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    Allarity Gets FDA Fast Track for Stenoparib in Ovarian Cancer
    Allarity Gets FDA Fast Track for Stenoparib in Ovarian Cancer

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.